Rgenix negotiates exclusive in-license with global pharmaceutical company
Clients Rgenix, Inc.
Jones Day represented Rgenix, Inc. in the negotiation of a license to a portfolio of drug candidates developed by a global pharmaceutical company in a non-cancer indication that Rgenix has identified as having use in treating cancer metastasis. Rgenix obtained issued patents in the U.S., Europe, and Japan, which provide composition of matter protection for its lead drug candidate. The license was a key milestone to enable the Company to raise venture capital to bring its lead melanoma drug candidate to clinical trials.